This study used a pseudovirus-based system to analyze how Bundibugyo virus (BDBV) enters host cells and to evaluate whether existing vaccines can induce neutralizing antibodies against BDBV.
The pseudovirus platform successfully modeled BDBV host cell entry and assessed vaccine-induced neutralisation; specific quantitative titers or efficacy figures are not extractable from the available abstract text.
Pseudovirus systems may not fully replicate authentic BDBV replication dynamics; results may not directly translate to in vivo protection; full numerical data are not available from the provided abstract alone.
Pseudovirus assays offer a BSL-2-compatible tool to screen cross-protective vaccine responses against Bundibugyo virus, which has no licensed vaccine; these findings can help prioritize filovirus vaccine candidates for further development.
